Stand Up To Cancer returns on August 15. The biennial fundraising event is scheduled to occur in Nashville this year, which ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

The new platform integrates PCR-based diagnostic data with statistical modeling and AI to provide real-time visibility into ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Results from the Phase III VEGA-3 trial show that a significantly higher number of patients with presbyopia who received ...

Results from the Phase III Vivacity-MG3 trial show that Imaavy provides more consistent disease control than other approved ...

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...